Starpharma Holdings Limited

In a quiet week for approvals, the US Food and Drug Administration acted in two relatively underserved areas: the common condition bacterial vaginosis, where the FDA cleared Daré Biosciences’ Xaciato,

Scrip regularly covers business development and deal-making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. MTEM Will Use Platform To Research Canc

British women suffering from recurring bacterial vaginosis can now turn to an antibiotic-free treatment thanks to the launch of Starpharma Holdings Ltd. ’s innovative VivaGel BV. Marketed in the UK b

A few new drug therapies could be on the horizon for some of the most common women’s health infections – vulvovaginal candidiasis and bacterial vaginosis – after years of efforts by the US Food and Dr